Aztreonam/avibactam
| Combination of | |
|---|---|
| Aztreonam | Monobactam antibacterial |
| Avibactam | Beta-lactamase inhibitor |
| Clinical data | |
| Trade names | Emblaveo |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a625054 |
| License data | |
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Aztreonam/avibactam, sold under the brand name Emblaveo, is a fixed-dose combination antibacterial medication used for the treatment of aerobic Gram-negative infections. It was developed by AbbVie and Pfizer, and is a combination of aztreonam, a monobactam antibacterial, and avibactam, a non-beta-lactam beta-lactamase inhibitor.
The combination was approved for medical use in the European Union in April 2024, in the United Kingdom in June 2024, and in the United States in February 2025.